How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Seasonal Influenza Vaccines Therapeutics Market
- By Vaccine Type: Inactivated Influenza Vaccines (IIV), Live Attenuated Influenza Vaccines (LAIV), Recombinant Influenza Vaccines (RIV), Adjuvanted Influenza Vaccines, High-Dose Influenza Vaccines
- By Target Age Group: Pediatric (6 months to 17 years), Adult (18 to 64 years), Geriatric (65 years and older)
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Government Immunization Programs, Clinics and Physician Offices
- By End User: Hospitals, Clinics, Public Health Organizations, Pharmacies
- By Technology Platform: Egg-based Vaccine Production, Cell-based Vaccine Production, Recombinant DNA Technology
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Inactivated Influenza Vaccines (IIV) leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Seasonal Influenza Vaccines Therapeutics Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 5
Target Age Group 3
Distribution Channel 4
End User 4
Technology Platform 3
Companies profiled
Sanofi Pasteur
GlaxoSmithKline (GSK)
Seqirus (a CSL company)
AstraZeneca
Bharat Biotech
Novartis (now part of CSL)
Mylan (now part of Viatris)
Baxter International
Sanofi
Sinovac Biotech
Boehringer Ingelheim
Panacea Biotec
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sanofi Pasteur
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Seqirus (a CSL company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AstraZeneca
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bharat Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis (now part of CSL)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Mylan (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Baxter International
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sinovac Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Boehringer Ingelheim
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Panacea Biotec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Serum Institute of India
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Shionogi & Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Janssen Pharmaceuticals (Johnson & Johnson)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,102M by 2033 · 11.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Inactivated Influenza Vaccines (IIV)54.9
- Live Attenuated Influenza Vaccines (LAIV)6.3
- Recombinant Influenza Vaccines (RIV)15.0
- Adjuvanted Influenza Vaccines13.3
- High-Dose Influenza Vaccines10.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$559.1M → $1,264M · 10.7%
Europe$389.7M → $910.3M · 11.2%
Asia Pacific$355.8M → $784.6M · 10.4%
Latin America$220.3M → $503.5M · 10.9%
Middle East and Africa$169.4M → $374.5M · 10.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.642026
11.652027
11.662028
11.672029
11.692030
11.692031
11.702032
11.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sanofi Pasteur20.6
- GlaxoSmithKline (GSK)13.5
- Seqirus (a CSL company)5.5
- AstraZeneca16.0
- Bharat Biotech11.0
- Novartis (now part of CSL)5.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type22.8%
Target Age Group22.1%
Distribution Channel11.5%
End User17.2%
Technology Platform26.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.9
- Europe23.7
- Asia Pacific20.4
- Latin America13.1
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sanofi Pasteur | 76 | 89 | 93 | 89 | 96 | 83 | 88 |
| GlaxoSmithKline (GSK) | 83 | 91 | 88 | 76 | 76 | 87 | 84 |
| Seqirus (a CSL company) | 88 | 70 | 82 | 64 | 84 | 62 | 75 |
| AstraZeneca | 78 | 65 | 60 | 68 | 81 | 78 | 72 |
| Bharat Biotech | 62 | 52 | 66 | 52 | 59 | 77 | 61 |
| Novartis (now part of CSL) | 68 | 54 | 61 | 64 | 69 | 55 | 62 |
| Mylan (now part of Viatris) | 54 | 66 | 50 | 45 | 49 | 51 | 53 |
| Baxter International | 51 | 37 | 49 | 57 | 49 | 58 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Seqirus (a CSL company)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sanofi Pasteur | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| GlaxoSmithKline (GSK) | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Seqirus (a CSL company) | ✓ | ◐ | ✓ | ✓ | ✓ | − |
| AstraZeneca | ✓ | − | ◐ | − | ✓ | ◐ |
| Bharat Biotech | ◐ | ◐ | ✓ | − | − | ✓ |
| Novartis (now part of CSL) | ✓ | − | ◐ | − | ◐ | ◐ |
| Mylan (now part of Viatris) | − | − | − | ◐ | − | − |
| Baxter International | ◐ | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sanofi Pasteur88
2GlaxoSmithKline (GSK)84
3Seqirus (a CSL company)75
4AstraZeneca72
5Novartis (now part of CSL)62
6Bharat Biotech61
7Mylan (now part of Viatris)53
8Baxter International50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Sanofi PasteurGlaxoSmithKline (GSK)
Challenger2
Strong scale, closing on the leaders.
Seqirus (a CSL company)AstraZeneca
Contender2
Focused players with pockets of strength.
Bharat BiotechNovartis (now part of CSL)
Niche2
Specialists in a single segment or region.
Mylan (now part of Viatris)Baxter International
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Seasonal Influenza Vaccines Therapeutics Market — a $191M beachhead inside a $2.60B market.
Beachhead (SOM)$191Mobtainable near-term
Serviceable (SAM)$1.03Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Inactivated Influenza Vaccines (IIV)
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer77 fit
Live Attenuated Influenza Vaccines (LAIV)
Strong fit — clear ROI and a fast path to value.
End user64 fit
Recombinant Influenza Vaccines (RIV)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Age Group & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel25%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Seasonal Influenza Vaccines Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation14%
Closed-won6%
$12.7KCAC
$61KLTV
4.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Seasonal Influenza Vaccines Therapeutics Market is a resilient opportunity — $4.15B by 2033, compounding at 3.3%.
TAM · 2025$3.20Btoday
TAM · 2033$4.15Bforecast
CAGR3.3%2027–2033
Cumulative$32.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.15BTotal addressable market
SAM$1.41BServiceable available market
SOM$229MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.3% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.15BLarge & growingTAM by 2033 at 3.3% CAGR
$1.41BServiceable nowreachable with today’s model
$229MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.24BBear2.1% CAGR
$4.15BBase3.3% CAGR
$5.31BBull4.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Age Group optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Seasonal Influenza Vaccines Therapeutics Market — a $5.47B market by 2033. Plan: grow share from 10.4% to 16.1%.
Market size · 2033$5.47Btotal addressable
Market CAGR8.7%2027–2033
Target share16.1%from 10.4% today
Revenue ambition$881Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.4% | 16.1% | On track |
| Revenue | $537M | $881M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 36.4% | 40.6% | On track |
| Customer retention | 85.8% | 93.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Age Group capability
A defensible second engine — invest in Target Age Group to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Age Group
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $90M capacity & capability investment
- Greenlight bolt-on M&A in Target Age Group
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Seasonal Influenza Vaccines Therapeutics Market conversation — a $6.56B market you can size, segment and defend in minutes.
Market size · 2033$6.56Btotal opportunity
Growth4.0%CAGR to 2033
Addressable buyers916+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 3 mopayback period
$84K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Sanofi PasteurGlaxoSmithKline (GSK)Seqirus (a CSL company)AstraZenecaBharat BiotechNovartis (now part of CSL)Mylan (now part of Viatris)Baxter International+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Seasonal Influenza Vaccines Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Seasonal Influenza Vaccines Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Scoliosis Management Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportChicken Vaccines Market
Market size, share, segmentation and regional forecast.
$364M market · 2025 base year
View reportPorcine Vaccines Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportAutoimmune Disease Diagnostics Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportAutoimmune and Inflammatory Immunomodulators Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportYervoy Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportHuman Immune Globulin Intravenous Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportDrugs for Lipid Metabolism Disease Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportAripiprazole Drug Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportAir-puff Tonometer Market
Market size, share, segmentation and regional forecast.
$308M market · 2025 base year
View reportNuclear Medicine Radiopharmaceutic Market
Market size, share, segmentation and regional forecast.
$966M market · 2025 base year
View reportSerotonin Supplement Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.